Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Income from Continuing Operations (2016 - 2025)

Standard Biotools (LAB) has disclosed Income from Continuing Operations for 16 consecutive years, with 43709000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 1595.35% to 43709000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 31706000.0 through Dec 2025, up 61.54% year-over-year, with the annual reading at 29062000.0 for FY2025, 56.42% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 43709000.0 at Standard Biotools, up from 31700000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 43709000.0 in Q4 2025, with the low at 76262000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 20805000.0, with a median of 20845000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 305.82% in 2022, then skyrocketed 1595.35% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 13865000.0 in 2021, then plummeted by 50.34% to 20845000.0 in 2022, then surged by 165.83% to 13723000.0 in 2023, then crashed by 121.3% to 2923000.0 in 2024, then surged by 1595.35% to 43709000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 43709000.0, 31700000.0, and 17682000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.